Target intelligence / Profile preview

Cerebral dopamine neurotrophic factor (CDNF)

Target
CDNF
Molecular classification
Neurotrophic factor, Secretory protein, Endoplasmic reticulum (ER)-resident protein, Signaling protein, Other (distinct family: not receptor/enzyme/transporter/classic growth factor)
01

Overview

Cerebral dopamine neurotrophic factor (CDNF) is a structurally unique neurotrophic protein belonging to an atypical family (with MANF/mesencephalic astrocyte-derived neurotrophic factor) that regulates endoplasmic reticulum stress and the unfolded protein response, conferring protection and promoting survival of neurons exposed to toxic, oxidative, or protein-misfolding stressors. CDNF operates both extracellularly as a trophic factor and intracellularly within the ER, and, unlike classic neurotrophic factors, does not act through a membrane receptor. Its most studied application is in Parkinson’s disease, where preclinical and early clinical results show neuroprotective and neurorestorative effects on dopaminergic neurons. CDNF’s functions span beyond dopamine modulation, playing roles in regulation of various neurotransmitter circuits, neuroplasticity, and suppression of inflammation and apoptosis. Due to these properties, CDNF and its derivatives are actively explored as therapeutic agents for neurodegenerative disorders.

Other names
CDNFARMETL1Cerebral dopamine neurotrophic factor protein
02

Mechanism of action

Exogenous (administered) CDNF protein enters cells, localizes to the endoplasmic reticulum, and regulates ER stress and UPR, leading to neuroprotection and prevention of neuronal death. Modulates inflammatory signaling and apoptosis pathways. Supports maturation and survival of various neuronal subtypes, especially dopaminergic neurons.

03

Biological functions

Regulation of ER stressModulation of unfolded protein response (UPR)NeuroprotectionSuppression of apoptosisModulation of inflammationNeuronal survivalRegulation of neurotransmitter system developmentPromotion of protein homeostasisSupport of neuron maturation and maintenanceRegulation of neuroplasticity
04

Disease associations

Neurodegenerative diseaseParkinson’s diseaseOther protein-misfolding diseasesPossibly involved in seizure disorders, neurodevelopmental and behavioral disorders
05

Safety considerations

No major safety concerns reported in early-phase human clinical trials for PD (Phase I-II), with CDNF considered safe and well-tolerated when administered directly to the brainPotential for off-target effects with systemic delivery, and the long-term effects in humans are still unknownAdequate delivery across the blood-brain barrier remains a challenge
06

Interacting drugs

No approved or widely recognized small-molecule drugs directly target CDNF as of now.

2 more in the full profile.

07

Biomarkers

Currently, no validated biomarkers are in routine use for patient selection or monitoring CDNF efficacy, but changes in ER stress markers, unfolded protein response proteins, and dopaminergic neuronal survival in models are researchedPhosphorylated forms of ER stress response proteins and dopamine neuron markers in preclinical models for exploratory evaluation

Beyond the preview

Go deeper on Cerebral dopamine neurotrophic factor (CDNF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerebral dopamine neurotrophic factor (CDNF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call